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Abstract
Objective: Diabetes mellitus type 2 (DM2) is a risk factor for coronary heart disease (CHD). While there is a clear
correlation of fasting blood glucose (FBG) and 2 h post-challenge blood glucose values (2h-BG) with microvascular
complications, the risk for CHD conferred by glucose dysregulation antecedent to DM2 is less clear. Therefore, we
investigated associations of FBG and 2h-BG values with the prevalence of CHD assessed by coronary angiography
as the most sensitive diagnostic tool.
Research Design and Methods: Coronary angiography was performed in 1394 patients without known DM.
Capillary blood glucose was analyzed before and 2 h after an oral glucose tolerance test. Associations between
FBG as well as 2h-BG levels and the risk for CHD were assessed by logistic regression analysis.
Results: 1064 (75%) of patients were diagnosed with CHD. 204 (15%) were diagnosed with so far unknown DM2,
274 (20%) with isolated impaired fasting glucose (IFG), 188 (13%) with isolated impaired glucose tolerance (IGT)
and 282 (20%) with both, IGT and IFG. We found a continuous increase in the risk for CHD with fasting and post-
challenge blood glucose values even in the subdiabetic range. This correlation did however not suggest clear cut-
off values. The increase in risk for CHD reached statistical significance at FBG levels of > 120 mg/dl (Odds Ratio of
2.7 [1.3-5.6] and 2h-BG levels > 140 mg/dl (141-160 mg/dl OR 1.8 [1.1-2.9], which was however lost after adjusting
for age, sex and BMI.
Conclusions: In our study population we found a continuous increased risk for CHD at fasting and 2h-BG levels in
the sub-diabetic glucose range, but no clear cut-off values for cardiovascular risk.
Keywords: impaired glucose tolerance, impaired fasting glucose, diabetes mellitus, oral glucose tolerance test, car-
diovascular disease
Introduction
Diabetes mellitus type 2 (DM2) is a major risk factor for
micro- and macrovascular complications like coronary
heart disease (CHD)[1,2]. While there is a clear correla-
tion of fasting blood glucose (FBG) and 2 h post-chal-
lenge blood glucose values (2h-BG) with microvascular
diseases, the risk for CHD conferred by glucose dysregu-
lation antecedent to DM2 is less clear. There is contro-
versial data concerning the correlation of blood glucose
levels in the sub-diabetic range (impaired fasting glucose
(IFG) and impaired glucose tolerance (IGT)) with the
cardiovascular risk. The controversies might be due to
different clinical end-points. Frequently used end-points
are all-cause and cardiovascular mortality. Using all-
cause mortality as an end-point Sorkin et al found a sig-
nificant 40% increase in risk when the FBG exceeded
110 mg/dl [3]. This was in line with the Rancho Ber-
nado study and the IPC Center study[4,5]. This increase
in mortality further doubled within the FBG range
between 126 mg/dl and 139 mg/dl[3]. There might also
be gender differences as data from the Rancho Bernado
study showed a significant increase in mortality within
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in women [6,7].
Consistently, a number of studies found a continuous
increase in all-cause mortality with FBG levels in the
sub-diabetic range although they did not reach statistical
significance[8-11].
On the other hand, there are data from other studies
reporting no correlation between FBG and mortality in
the subdiabetic range[6].
Similarly, the relation between IGT and cardiovascular
risk remains unclear. The ARIC study for example
found no association of IGT with cardiovascular risk
over a 6.3 year follow-up period[12]. However, the lar-
gest meta-analysis in that area including 20 prospective
studies and almost 100 000 individuals revealed an
increased cardiovascular risk for people with IGT when
analysing clinical cardiovascular events[13].
In order to clarify the association of subdiabetic glu-
cose values and cardiovascular risk we have chosen cor-
onary angiography as a sensitive clinical end-point in
the current study. Coronary atherosclerosis precedes the
clinical manifestation of CHD and can be diagnosed
early by coronary angiography. Patients undergoing cor-
onary angiography show a high prevalence of undiag-
nosed glucose abnormalities[14]. There is only limited
data on the correlation of glucose dysregulation with
coronary atherosclerosis assessed by angiography. The
only large cohort (n = 1040) has been reported by Saely
and colleagues. They investigated the relation of
impaired glucose tolerance (2h-BG levels in an oGTT)
with angiographically characterised coronary athero-
sclerosis. They found IGT to be associated with an
increased prevalence of coronary atherosclerosis but not
with significant stenosis (defined as lumen narrowing >
50%)[15]. To our knowledge there is no data from a
large cohort on angiographically assessed CHD in corre-
lation to fasting blood glucose levels in the subdiabetic
range. Therefore, the aim of this study was to investigate
if the prevalence of coronary stenosis assessed by coron-
ary angiography is increased at subdiabetic glucose
levels.
Methods
Study population
All patients (n = 1394) without known DM2 that have
been submitted to the heart center Wuppertal (Ger-
many) for elective coronary angiography between 2007
and 2009 were enrolled in this retrospective study. The
study was performed according to the rules of the
Declaration of Helsinki and all study patients gave
informed written consent. The clinical and demographic
data obtained for each patient included sex, age, body
mass index (BMI), history of CHD and actual cardiovas-
cular intervention.
Determination of coronary and glycaemic state
In each patient, coronary angiography was performed at
least one day before the oGTT. Coronary heart disesase
(CHD) was diagnosed in the presence of a luminal nar-
rowing ≥50% of any epicardial vessel. An oGTT with 75
g (DextroOGT, Roche Diagnostics, Mannheim, Ger-
many) was performed and capillary blood glucose was
measured before and 2 h after oral glucose load with a
point-of-care system (ecoSolo II; CAREdiagnostica),
which is based on enzymatic, amperometric measure-
ment using a GOD-H202 electrode. Coefficient of varia-
tion was about 5%. Of note, classifications of glycaemic
state were made according to the criteria of the German
Diabetes Association (Deutsche Diabetes Gesellschaft)
for capillary blood glucose (IFG > 90 mg/dl; IGT > 140
mg/dl; DM2 ≥ 110 mg/dl (fasting) or ≥ 200 mg/dl (2h-
BG after oGTT)). For one patient the FBG value was
missing. 2h-BG values were missing for 20 patients
since there FBG values had been considerably higher
than 110 mg/dl. Therefore, OGTT had not been per-
formed in those cases and DM2 had been diagnosed
based on the FBG values.
Statistical analysis
Logistic regression analysis with adjustment to sex and
age was used to determine the influence of FBG or 2h-
BG on CHD risk. Associations were determined by
Spearman correlation. The level of significance was 0.05.
For data analysis GraphPad Prism 4.0 (GraphPad Soft-
ware, San Diego, CA, USA) and SAS statistical package
version 8.2 TS2MO (SAS Institute, Cary, NC, USA)
were used.
Results
High prevalence of coronary heart disease in the study
population
In this study we enrolled 1,394 patients without known
DM2 who underwent elective coronary angiography.
The patient characteristics are given in Table 1. As
shown here, 76% of the patients were diagnosed with
CHD based on the lumen narrowing ≥50% diagnosed by
coronary angiography. The prevalence of CHD corre-
lated with age (r = 0.12, p < 0.0001), male sex (r = 0.23;
p < 0.0001), the diagnosis of DM2 (r = 0.08; p = 0.003),
FBG (r = 0.07; p = 0.009), and 2H-BG (r = 0.14; p <
0.0001). Using an oGTT 15% of the patients were iden-
tified with so far unknown DM2, 20% with isolated IFG,
13% with isolated IGT and 20% with both IGT and IFG.
Only 32% were normoglycaemic (Table 1).
Increased risk for coronary heart disease with blood
glucose levels in the subdiabetic range
Capillary blood glucose was determined in the fasting
state and 2 h after an oGTT. The distribution of FBG
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were < 90 mg/dl (329 with CHD vs. 106 without CHD),
370 (26%) were in the range of 91-100 mg/dl (292 vs.
78), 164 (12%) were between 101-110 mg/dl (124 vs.
40), 76 (6%) were between 111-120 mg/dl (62 vs. 14)
and 72 (5%) were > 120 mg/dl (63 vs. 9) (Figure 1A).
Patients with FBG ≤80 mg/dl (n = 276 (20%); 200 vs.
76) were defined as the reference group. Compared to
the reference group the risk for CHD increased continu-
ously with FBG levels. Table 2 shows that statistical sig-
nificance was reached at FBG levels > 120 mg/dl (OR
2.67 [1.3-5.6]) and remained significant after adjusting
for sex and age but not in a separate model including
t h eB M I .A ss e e ni nT a b l e3w h e nb l o o dg l u c o s ew a s
expressed as a continuous variable, both the fasting as
well as the 2 h glucose values were significantly corre-
lated with CHD risk.
Consistently, Table 4 shows a continuous risk incre-
ment for CHD over the whole range of glucose levels.
When analysing post-challenge glucose, we found 181
(13%) of the patients had 2h-BG values ranging 101-120
mg/dl (196 vs. 67), 291 (21%) were in the range of 121-
140 mg/dl (200 vs. 91), 212 (15%) in the range of 141-
160 mg/dl (170 vs. 42), 161 (12%) were between 161-
180 mg/dl (142 vs. 19), and 266 (19%) were > 180 mg/dl
(221 vs. 45) (Figure 1B). Patients with 2h-BG levels
≤100 mg/dl (n = 181 (13%); 125 vs. 56) were defined as
the reference group. Similarly to our findings for fasting
glucose the CHD risk increased at subdiabetic 2 h glu-
cose levels with an increased risk for CHD with an OR
1.80 [1.1-2.9] for patients within the glucose range of
141-160 mg/dl, 2.2 [1.4-3.4] for those within 161-180
mg/dl and 3.3 [1.8-5.8] for patients whose 2h-BG
exceeded 180 mg/dl (Table 2).
Discussion
In our study population 76% of patients were diagnosed
w i t hC H Da n d1 5 %w i t hs of a ru n k n o w nD M 2 ,2 0 %
with IFG, 13% with IGT and 20% with both, IFG and
IGT. DM2 is a major risk factor for coronary heart dis-
ease[16]. However, the diagnostic thresholds to define
diabetes are based on microvascular endpoints. There-
fore, it is not clear whether microvascular and CHD risk
increases at the same glucose thresholds. In our study,
the risk for CHD as assessed by coronary angiography
increased with the blood glucose levels even in the sub-
diabetic range. However, we found a rather continuous
increase of CHD risk with blood glucose. In the fasting
state the increase in risk reached statistical significance
only when the capillary fasting glucose levels were > 120
mg/dl. It is important to note that the diabetes thresh-
old in the fasting state in capillary blood is ≥ 110 mg/dl.
Therefore, in our study IFG increased the risk for CHD
but did not reach statistical significance. When analysing
post-challenge glucose values we found a significant
increase in CHD risk even at the level of IGT. The ana-
lysis of the combination of all grades of glucose distur-
bancies (IFG, IGT and diabetes) revealed a positive and
significant correlation with CHD (table 3).
T h e r ei so n g o i n gd e b a t ei ft h e r ei sa ta l lac l e a r
threshold for CHD risk or rather a continuous increase
with increasing blood glucose levels. Therefore, the
most important finding in our study is the increase in
the prevalence of coronary heart disease with blood glu-
cose levels in the subdiabetic range. Our results are in
line with a large retrospective meta-analysis including
95,000 patients demonstrating an increase for cardiovas-
cular events even at sub-diabetic glucose levels[13]. In
addition, a recent meta-analysis identified a positive cor-
relation between IGT and carotid intima media thick-
ness as a marker for cardiovascular risk[17]. In line with
this study we found that postprandial hyperglycaemia
contributes more to CHD than fasting hyperglycaemia.
However, various investigations on this question yielded
controversial data. For example in the prospective ARIC
(Atherosclerosis Risk in Communities) study there was
no association of isolated IFG or IGT with cardiovascu-
lar risk. In line with this, a recent study by Pereg and
colleagues attributed the progressive increase in cardio-
vascular risk at fasting glucose levels in the upper nor-
mal range to the prevalence of comorbidities rather
than to glucose effects[18].
Notably, the endpoints in this study - as in most other
similar studies - were clinical events. This included all
cause mortality, clinically incident CHD and surrogate
parameters for cardiovascular risk e.g. intima-media
Table 1 Patient characteristics
Patients (n = 1394)
Sex [n] (male/female) 962 (69%)/432 (31%)
Age [years] 64.0 ± 11.4
Body Mass Index [kg/m
2] 27.6 ± 4.5
CHD [n] 1064 (76%)
Acute myocardial infarction [n] 294 (21%)
CHD before [n] 579 (42%)
FBG [mg/dl] 92.5 ± 16.2
2h-BG [mg/dl] 145.0 ± 43.1
NGT [n] 446 (32%)
Isolated IFG [n] 274 (20%)
Isolated IGT [n] 188 (13%)
IFG/IGT [n] 282 (20%)
DM2 [n] 204 (15%)
CHD, coronary heart disease; FBG, fasting blood glucose; 2h-BG, blood glucose
2 h after 75 g oral glucose challenge; NGT, normal glucose tolerance; IFG,
impaired fasting glucose; IGT, impaired glucose tolerance; DM, diabetes
mellitus
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Figure 1 Cumulative frequency of fasting and 2 h blood glucose values for patients with and without coronary heart disease.
Cumulative frequencies of patients with and without coronary heart disease (CHD) were plotted against blood glucose values in (A) fasting state
and (B) 2 h after an oral glucose tolerance test. Blood glucose ranges were divided into sextiles with the lowest sextile defined as reference
group each. Shown are the numbers and percentages of patients as well as the odds ratios for CHD in the respective blood glucose sextiles.
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Page 4 of 7thickness, ankle-brachial blood pressure index and left
ventricular hypertrophy.
However, coronary angiography is the current diag-
nostic gold standard for early detection of coronary
artery disease[19]. Therefore, we investigated the corre-
lation of blood glucose levels with data from patients
undergoing elective coronary angiography.
Although patients with known DM2 had not been
included in the study, two thirds of the patients had
either IFG, IGT, or newly DM2 and only 32% of the
patients included turned out to be normoglycaemic.
This is in line with previous data[14,20] and
furthermore emphasises the importance of diagnostic
efforts to detect DM2 in pati e n t ss u s p i c i o u sf o rC H D .
How reliable are these oGTT data gained in hospital? A
recent study reported follow-up data from oGTT tests
done in hospital and after three months in patients with
ST-elevation myocardial infarction. They found a large
part of the study population to change the metabolic
state with time[21]. However, it is not known, whether
the patients were still critically ill during the in hospital
oGTT. In our current study we had a different situation
as we excluded patients with acute myocardial
infarction.
There is very limited data on cardiovascular athero-
sclerosis assessed by angiography with respect to sub-
diabetic glucose levels. Earlier studies including rela-
tively small numbers of patients that investigated the
correlation of IGT with coronary artery disease by
angiography demonstrated controversial results[22-25].
Only one large study by Saely and colleagues investi-
gated coronary atherosclerosis by angiography with
respect to IGT and found a positive correlation. In addi-
tion to this, our study correlates the risk for CHD
defined as significant lumen narrowing with IGT and
with distinct levels of FBG in the sub-diabetic range.
We confirm the significant increase in CHD with IGT.
I na d d i t i o n ,t h e r ei st h es a m et r e n do fac o n t i n u o u s
increase in CHD risk for fasting glucose values in the
subdiabetic range; the effect was however significant
only above the diabetes threshold. To our knowledge,
this is the first study investigating this correlation in a
large cohort of patients undergoing angiography. One
hypothesis to explain this finding is that post-challenge
glucose excursions contribute a greater CHD risk than
slightly elevated fasting levels.
Table 2 Association between blood glucose levels and
coronary heart disease.
fasting blood glucose
[mg/dl]
rohes OR
[CI]
adj. OR [CI]
1 adj. OR [CI]
2
≤ 80 (reference) 1.00 1.00 1.00
81-90 1.18 [0.88-
1.66]
1.13 [0.79-
1.64]
1.15 [0.78-
1.71]
91-100 1.42 [0.99-
2.04]
1.24 [0.85-
1.81]
1.27 [0.84-
1.92]
101-110 1.17 [0.75-
1.83]
1.04 [0.65-
1.67]
1.12 [0.67-
1.87]
111-120 1.69 [0.89-
3.20]
1.39 [0.71-
2.74]
1.41 [0.67-
2.97]
> 120 2.67 [1.27-
5.64]
2.50 [1.15-
5.46]
2.27 [0.93-
5.31]
2 h blood glucose [mg/
dl]
≤ 100 (reference) 1.00 1.00 1.00
101-120 1.30 [0.86-
1.98]
1.17 [0.74-
1.82]
0.99 [0.61-
1.60]
121-140 0.99 [0.66-
1.47]
0.87 [0.56-
1.33]
0.74 [0.46-
1.17]
141-160 1.80 [1.14-
2.86]
1.45 [0.89-
2.38]
1.48 [0.86-
2.53]
161-180 2.17 [1.40-
3.37]
2.18 [1.18-
4.06]
1.76 [0.90-
3.45]
> 180 3.25 [1.83-
5.78]
1.53 [0.92-
2.53]
1.44 [0.80-
2.57]
1 adjusted for sex and age
2 adjusted for sex, age and bmi
Table 2 Associations between blood glucose levels/
glucose tolerance state and coronary heart disease
raw OR [CI] adj. OR [CI]
1 adj. OR [CI]
2
fasting blood
glucose
1.013
[1.004-1.022]
1.010
[1.001-1.019]
1.010
[1.000-1.020]
2 h blood glucose 1.008
[1.005-1.011]
1.007
[1.003-1.010]
1.007
[1.003-1.011]
NGT/IFG+IGT/DM2
combined
1.571
[1.292-1.910]
1.401
[1.147-1.727]
1.446
[1.158-1.807]
1 adjusted for sex and age
2 adjusted for sex, age and B.M.I.
Table 4 Difference in numbers of patients with or
without coronary heart disease at defined blood glucose
levels
fasting blood glucose [mg/dl] p
≤ 80 vs. > 80 0.067
≤ 90 vs. > 90 0.031
≤ 100 vs. > 100 0.171
≤ 110 vs. > 110 0.018
≤ 120 vs. > 120 0.031
2 h blood glucose [mg/dl]
≤ 80 vs. > 80 0.153
≤ 90 vs. > 90 0.001
≤ 100 vs. > 100 0.011
≤ 100 vs. > 100 0.009
≤ 100 vs. > 100 < 0.0001
≤ 100 vs. > 100 < 0.0001
≤ 100 vs. > 100 0.006
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spective study, therefore not directly allowing the pre-
diction of future cardiovascular risk in patients at a
given sub-diabetic glucose level. Second, we did not
have the option to concisely include effects of co-medi-
cation (e.g. acetylsalicylic acid, statins) in our analysis.
T h i r d ,w ed i dn o th a v eac h a n c et oe v a l u a t et h ee x t e n t
of coronary atherosclerosis. Instead, we defined the diag-
nosis of significant coronary stenosis when lumen nar-
rowing was ≥50%. However, based on the high number
of patients included (n = 1394) we are confident that
the effects of blood glucose on coronary atherosclerosis
observed in our study are robust and reliable to assess
the risk for coronary heart disease in the sub-diabetic
glucose range. Interestingly, Saely et al. found a signifi-
cant increase in the prevalence of coronary atherosclero-
sis (defined as any visible lumen narrowing) in patients
with IGT but this was not significant for relevant steno-
sis (defined as lumen narrowing > 50%). On the other
hand, they found 2h-BG as a continuous variable to be
significantly correlated with both prevalence of athero-
sclerosis and relevant stenosis[19]. In addition, a recent
follow-up study on this population over 3.8 years
showed a positive correlation of IFG with future cardio-
vascular events[26]. In line with this, we found not only
2 h - B Gb u ta l s oF B Gt ob ec o n t i n u o u s l yc o r r e l a t e dw i t h
increased prevalence of significant coronary stenosis.
This seems to be in contrast to the effects of blood glu-
cose on microvascular endpoints which show a steep
i n c r e a s eo fr i s ka td i s t i n c tb l o o dg l u c o s ev a l u e s .A p p a r -
ently, the risk of cardiovascular complications conferred
by glucose is more a continuous gradual increase. This
is important in identifying people at risk for cardiovas-
cular disease in populations that do not fulfil the current
diagnostic criteria of DM2. Taken together; our study
demonstrates a continuous increase in cardiovascular
risk at sub-diabetic glucose levels in patients undergoing
elective coronary angiography.
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